Voices
Shaheenah Dawood: PFS Among BRCA1/2 and PALB2 Mutation Carriers on First-Line Therapy
Shaheenah Dawood/mediclinic.ae

Shaheenah Dawood: PFS Among BRCA1/2 and PALB2 Mutation Carriers on First-Line Therapy

Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:

“Real world dataset

BRCA1/2 and PALB2 mutation carriers had reduced PFS with first-line ET + CDK4/6i compared to wild-type patients.

The median OS was 49.0 months for BRCA/PALB2m, 50.4 months for BRCA/PALB2wt, and 52.8 for untested patients, with no significant differences observed among the groups.”

Title: BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer

Authors: Timothé Guinela, Amélie Lusqueb, Audrey Mailliez, Vincent Massard, William Jacot, Severine Guiue, Thibault de la Motte Rouge, Etienne Braing, Isabelle Desmoulinsh, Monica Arnedos, Caroline Bailleux, Anthony Goncalves, Christelle Levy, Thomas Bachelot, Lise Bosquet, Suzette Delaloge, Jean-Sébastien Frénel

Read the Full Article.

Shaheenah Dawood: PFS Among BRCA1/2 and PALB2 Mutation Carriers on First-Line Therapy

Other articles featuring Shaheenah Dawood.

Amélie Lusqueb Anthony Gonçalves Audrey Mailliez cancer Caroline Bailleux Christelle Levy Etienne Braing Isabelle Desmoulinsh Jean-Sébastien Frénel Lise Bosquet Monica Arnedos OncoDaily Oncology Severine Guiue Shaheenah Dawood Suzette Delaloge Thibault de la Motte Rouge Thomas Bachelot Timothé Guinela Vincent Massard William Jacot